Table 3 Antiplatelet/anticoagulation management
From: In-office laryngeal procedures (IOLP) in Canada: current safety practices and procedural care
Would Continue N = 15 (%) | Would StopaN = 15 (%) | Would perform IOLP if patient cannot stop | |
|---|---|---|---|
ASA 81 mg | 11 (73.3) | 4 (26.7) | 15 (100.0) |
NSAIDs | 12 (80.0) | 3 (20.0) | 13 (86.7) |
Clopidogrel | 5 (33.2) | 10 (66.7) | 7 (46.7) |
New agents (i.e. dabigatran) | 8 (53.5) | 7 (46.7) | 5 (33.3) |
Warfarin | 3 (20.0)b | 12 (80.0) c | 4 (26.7)d |